New development of global drugs for prevention and treatment of chronic kidney diseases

GAO Yuehong; WANG Chunli; MAO Yanyan; LIU Lili

doi:10.3981/j.issn.1000-7857.2021.05.011

PDF(605 KB)

Science & Technology Review ›› 2021, Vol. 39 ›› Issue (5) : 99-105. DOI: 10.3981/j.issn.1000-7857.2021.05.011

Review

New development of global drugs for prevention and treatment of chronic kidney diseases

Author information -

Information Center, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai 201203, China

Abstract

Chronic kidney disease (CKD) has become a global public health problem due to its complex etiology and difficult treatment. CKD affects about 10% of the world's population and can lead to higher risks of cardiovascular disease and death. One of the key links of CKD prevention and treatment is to prevent or delay the progress of CKD. This article summarizes the epidemiology, risk factors, R&D investment and preventive and therapeutic drugs of CKD in order to understand the current situation and new preventive and therapeutic progress of CKD.

Key words

chronic kidney disease / risk factors / research and development investment / preventive and therapeutic drugs

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

GAO Yuehong, WANG Chunli, MAO Yanyan, LIU Lili. New development of global drugs for prevention and treatment of chronic kidney diseases[J]. Science & Technology Review, 2021, 39(5): 99-105 https://doi.org/10.3981/j.issn.1000-7857.2021.05.011

References

[1] Levey A S, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem:approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes[J]. Kidney International, 2007, 72(3):247-259.
[2] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification and stratification[J]. American Journal of Kidney Diseases, 2002, 39(S1):1-246.
[3] Turolo S, Edefonti A, Syren M L, et al. Fatty acids in nephrotic syndrome and chronic kidney disease[J]. Journal of Renal Nutrition, 2018, 28(3):145-155.
[4] Cañadas-Garre M, Anderson K, McGoldrick J, et al. Genomic approaches in the search for molecular biomarkers in chronic kidney disease[J]. Journal of Translational Medicine, 2018, 16(1):292.
[5] Anders H J, Huber T B, Isermann B, et al. CKD in diabetes:Diabetic kidney disease versus nondiabetic kidney disease[J]. Nature Reviews Nephrology, 2018, 14(6):361-377.
[6] Rodrigues J C, Haas M, Reich H N. IgA Nephropathy[J]. Clinical Journal of the American Society of Nephrology, 2017, 12(4):677-686.
[7] Almaani S, Meara A, Rovin B H. Update on Lupus Nephritis[J]. Clinical Journal of the American Society of Nephrology, 2017, 12(5):825-835.
[8] Kidney disease:Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney International, 2013, 3(Sl):1-150.
[9] Drawz P, Rahman M. Chronic kidney disease[J]. Annals of Internal Medicine, 2015, 162(11):1-16.
[10] Mayoclinic. Chronic kidney disease[EB/OL].[2020-03-12]. https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/symptoms-causes/syc-203545-21.
[11] Morris A P, Le T H, Wu H, et al. Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies[J]. Nature Communications, 2019, 10(1):29.
[12] Webster A C, Nagler E V, Morton R L, et al. Chronic kidney disease[J]. Lancet, 2017, 389(10075):1238-1252.
[13] Saran R, Robinson B, Abbott K C, et al. Us renal data system 2017 annual data report:Epidemiology of kidney disease in the United States[J]. American Journal of Kidney Diseases, 2018, 71(S1):7.
[14] 医药经济报. 政策利好独立透析中心进入开荒期[EB/OL].[2019-09-16]. ttp://www.yyjjb.com.cn/yyjjb/201809/20180904150837837_593.shtml.
[15] Levin A. Global challenges in kidney diseases[J]. Nephrology Dialysis Transplantation, 2018, 33(3):371-372.
[16] 胡盛寿, 高润霖, 刘力生, 等.《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3):209-220.
[17] Zhang L, Wang H, Long J, et al. China kidney disease network (CK-NET) 2014 annual data report[J]. American Journal of Kidney Diseases, 2017, 69(6):1-149.
[18] Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease[J]. Nature Reviews Disease Primers, 2017(3):17088.
[19] NIH. Chronic kidney disease and kidney failure[EB/OL].[2019-09-16]. https://archives.nih.gov/asites/report/09-09-2019/report.nih.gov/nihfactsheets/ViewFactSheet8604.html?csid=34&key=C#C.
[20] 日本健康和医疗战略推进总部. 平成30年度医療分野の研究開発関連予算のポイント[EB/OL].[2019-09-16]. http://www.kantei.go.jp/jp/singi/kenkouiryou/siryou/pdf/h30_yosan.pdf.
[21] 科技部. 科技部关于发布国家重点研发计划大气污染成因与控制技术研究等重点专项2018年度项目申报指南的通知[EB/OL].[2019-09-16]. http://www.most.gov.cn/mostinfo/xinxifenlei/fgzc/gfxwj/gfxwj2017/201712/t20171212_136764.htm.
[22] Andrassy K M. Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney International, 2013, 84(3):622-623.
[23] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志, 2017, 37(1):28-34.
[24] 胡仁明. 糖尿病肾病的诊断和防治——中国糖尿病肾病诊断和治疗的专家共识解读[J]. 糖尿病天地·临床, 2015, 9(9):447-453.
[25] 医脉通. 新型肾脏药Etelcalcetide获FDA批准[EB/OL].[2019-09-16]. http://news.medlive.cn/neph/info-progress/show-123984.html.
[26] 生物谷. 重磅! 全球首创肾性贫血新药罗沙司他(roxadustat)在中国率先获批[EB/OL].[2019-09-16]. http://news.bioon.com/article/6731474.html.
[27] 佰傲谷BioValley. 罗沙司他再下一城, 获得日本批准[EB/OL].[2019-09-16]. https://mp.weixin.qq.com/s/W60w0SfxwbWEv-yNyiNgww.
[28] 张晓丹, 解染, 崔一民. 肾病综合征患者个体化应用他克莫司的病例分析[J]. 中国临床药理学杂志, 2018, 34(19):2345-2347.
[29] 医脉通. Lokelma:肾病高钾血症又一治疗药获批[EB/OL].[2019-09-16]. http://news.medlive.cn/neph/infoprogress/show-142982_161.html.
[30] 林美棣, 孙伟. 健脾益肾法治疗慢性肾病研究现状[J]. 国医论坛, 2018, 33(2):65.
[31] 夏中尚, 杜正彩, 侯小涛, 等. 基于755首中药处方治疗糖尿病用药规律的研究[J]. 中草药, 2018, 49(3):739-744.
[32] 国家医疗保障局. 国家医保局人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录》的通知[EB/OL].[2019-09-16]. http://www.nhsa.gov.cn/art/2019/8/20/art_37_1666.html.
[33] 中国中西医结合学会肾脏疾病专业委员会, 中国中药协会肾病中药发展研究专业委员会. 肾康制剂(肾康注射液、肾康栓)治疗慢性肾脏病合理应用专家共识[J]. 中国中西医结合杂志, 2019, 39(7):784-786.